510(k) SUMMARY

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510(k) number is: KO50202

Submitter's Name and Address

Beckman Coulter, Inc.
1000 Lake Hazeltine Drive
Chaska, MN 55318
Telephone: (952) 368-1323
Fax: (952) 368-7610
Contact: Brent Taber

Date Prepared: January 27, 2005

Device Names

Proprietary Name: Cortisol and Cortisol Calibrators on the Access® Immunoassay Systems

Common Name: Cortisol (hydrocortisone and hydroxycorticosterone) test system

Classification Name: Radioimmunoassay, Cortisol

Predicate Device

Access Cortisol Assay
Beckman Coulter, Inc.
1000 Lake Hazeltine Drive
Chaska, MN 55318

510(k) Number: k954733
Device Description

The Access Cortisol reagents, Access Cortisol Calibrators and the Access Immunoassay Analyzers (Access, Access 2, Synchron LXi 725, and UniCel Dxl 800) comprise the Access Immunoassay Systems for the quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine.

Intended Use

The Access Cortisol assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine using the Access Immunoassay Systems.

Comparison of Technological Characteristics

<table>
<thead>
<tr>
<th>Attribute</th>
<th>Access Cortisol Assay</th>
<th>Cortisol and Cortisol Calibrators on the Access Immunoassay Systems</th>
</tr>
</thead>
<tbody>
<tr>
<td>Methodology</td>
<td>Competitive binding immunoenzymatic assay</td>
<td>Competitive binding immunoenzymatic assay</td>
</tr>
<tr>
<td>Intended Use</td>
<td>Quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine</td>
<td>Quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine</td>
</tr>
<tr>
<td>Solid Phase</td>
<td>Paramagnetic particles coated with goat anti-rabbit IgG</td>
<td>Paramagnetic particles coated with goat anti-rabbit IgG</td>
</tr>
<tr>
<td>Conjugate</td>
<td>Cortisol-alkaline phosphatase (bovine) conjugate</td>
<td>Cortisol-alkaline phosphatase (bovine) conjugate</td>
</tr>
<tr>
<td>Calibrators</td>
<td>Human serum containing cortisol (purified chemical compound) at levels of 0 and approximately 2, 5, 10, 25, and 60 μg/dL</td>
<td>Human serum containing cortisol (purified chemical compound) at levels of 0 and approximately 2, 5, 10, 25, and 60 μg/dL</td>
</tr>
</tbody>
</table>
Summary of Technological Characteristics

The device modification consists of a change to the directional insert. Cross-reactivity of the assay with substances that are similar in structure to cortisol was revised in the ‘Analytical Specificity / Interferences’ section. Urine cortisol concentration in 24-hour urine samples determined by extracted and unextracted methods was revised in the ‘Expected Values’ section.

Conclusion

Cortisol and Cortiosl Calibrators on the Access Immunoassay Systems is substantially equivalent to the Access Cortisol assay for the quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine.
I. continued...

C. Indications for Use Statement

The indications for use statement appears on the following page.
Mr. Brent Taber  
Staff Regulatory Specialist  
Beckman Coulter, Inc.  
1000 Lake Hazeltine Drive  
Chaska, MN 55318-1084

Re: k050202  
Trade/Device Name: Cortisol and Cortisol Calibrators on the Access® Immunoassay Systems  
Regulation Number: 21 CFR 862.1205  
Regulation Name: Cortisol (hydrocortisone and hydroxycorticosterone) test system  
Regulatory Class: Class II  
Product Code: CGR, JIS  
Dated: January 27, 2005  
Received: January 28, 2005

Dear Mr. Taber:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA’s issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act’s requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); and good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820).
This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific information about the application of labeling requirements to your device, or questions on the promotion and advertising of your device, please contact the Office of In Vitro Diagnostic Device Evaluation and Safety at (240)276-0484. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html

Sincerely yours,

Jean M. Cooper, MS, D.V.M.
Director
Division of Chemistry and Toxicology
Office of In Vitro Diagnostic Device Evaluation and Safety
Center for Devices and Radiological Health

Enclosure
Indications for Use

510(k) Number (if known): k050202

Device Name: Cortisol and Cortisol Calibrators on the Access® Immunoassay Systems

Indications For Use:

The Access Cortisol assay is a paramagnetic particle, chemiluminescent immunoassay for the quantitative determination of cortisol levels in human serum, plasma (heparin, EDTA) and urine using the Access Immunoassay Systems.

A cortisol (hydrocortisone and hydroxycorticosterone) test system is a device intended to measure the cortisol hormones secreted by the adrenal gland in serum, plasma and urine. Measurements of cortisol are used in the diagnosis and treatment of disorders of the adrenal gland.

Prescription Use X AND/OR Over-The-Counter Use
(21 CFR 801 Subpart D) (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

Page 1 of 1